Middle East Healthcare Company
TADAWUL:4009.SR
68.6 (SAR) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SAR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,653.17 | 2,151.744 | 1,872.621 | 1,772.21 | 1,496.647 | 1,390.69 | 1,629.43 | 1,615.641 | 1,534.528 | 1,398.752 | 828.36 | 542.222 |
| Cost of Revenue
| 1,681.397 | 1,471.735 | 1,264.441 | 1,172.21 | 1,023.716 | 889.943 | 864.522 | 787.918 | 724.393 | 655.366 | 401.212 | 295.296 |
| Gross Profit
| 971.773 | 680.009 | 608.18 | 599.999 | 472.931 | 500.747 | 764.907 | 827.723 | 810.135 | 743.386 | 427.148 | 246.926 |
| Gross Profit Ratio
| 0.366 | 0.316 | 0.325 | 0.339 | 0.316 | 0.36 | 0.469 | 0.512 | 0.528 | 0.531 | 0.516 | 0.455 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 132.135 | 83.967 | 102.412 | 87.51 | 53.973 | 315.616 | 82.07 | 283.576 | 261.598 | 233.571 | 138.319 | 88.99 |
| Selling & Marketing Expenses
| 51.077 | 30.383 | 45.965 | 31.143 | 14.777 | 10.173 | 11.91 | 181.309 | 162.353 | 189.951 | 146.979 | 84.829 |
| SG&A
| 623.109 | 114.351 | 148.377 | 118.653 | 68.75 | 324.135 | 93.98 | 464.886 | 423.951 | 423.521 | 285.298 | 173.819 |
| Other Expenses
| -0.521 | 420.807 | 397.203 | 351.615 | 298.988 | -338.016 | 15.06 | -7.244 | -8.254 | 0 | 0 | 0 |
| Operating Expenses
| 623.63 | 535.158 | 545.58 | 470.268 | 367.738 | -338.016 | 488.197 | 457.641 | 415.697 | 407.046 | 285.884 | 175.73 |
| Operating Income
| 348.143 | 140.341 | 54.245 | 126.402 | 103.267 | 162.731 | 275.366 | 370.082 | 394.438 | 313.177 | 128.697 | 65.439 |
| Operating Income Ratio
| 0.131 | 0.065 | 0.029 | 0.071 | 0.069 | 0.117 | 0.169 | 0.229 | 0.257 | 0.224 | 0.155 | 0.121 |
| Total Other Income Expenses Net
| -140.881 | -59.122 | -35.012 | -26.726 | -7.984 | 7.935 | 3.062 | 5.094 | -4.47 | 12.346 | 11.217 | 5.758 |
| Income Before Tax
| 201.618 | 81.218 | 19.232 | 99.676 | 95.283 | 170.666 | 278.428 | 358.754 | 389.968 | 332.211 | 140.122 | 71.197 |
| Income Before Tax Ratio
| 0.076 | 0.038 | 0.01 | 0.056 | 0.064 | 0.123 | 0.171 | 0.222 | 0.254 | 0.238 | 0.169 | 0.131 |
| Income Tax Expense
| 17.983 | 9.616 | 7.5 | 5.5 | 5.175 | 6.1 | 5.465 | 0.048 | 0.002 | 0.585 | 3.534 | 2.504 |
| Net Income
| 180.176 | 75.183 | 11.732 | 81.993 | 97.568 | 172.249 | 300.083 | 361.86 | 390.249 | 331.969 | 137.198 | 61.994 |
| Net Income Ratio
| 0.068 | 0.035 | 0.006 | 0.046 | 0.065 | 0.124 | 0.184 | 0.224 | 0.254 | 0.237 | 0.166 | 0.114 |
| EPS
| 1.96 | 0.82 | 0.13 | 0.89 | 1.06 | 1.87 | 3.47 | 3.94 | 4.24 | 3.61 | 1.49 | 0.67 |
| EPS Diluted
| 1.96 | 0.82 | 0.13 | 0.89 | 1.06 | 1.87 | 3.47 | 3.94 | 4.24 | 3.61 | 1.49 | 0.67 |
| EBITDA
| 551.237 | 297.413 | 212.899 | 243.827 | 220.732 | 251.681 | 387.895 | 421.964 | 446.733 | 357.722 | 184.202 | 100.375 |
| EBITDA Ratio
| 0.203 | 0.137 | 0.109 | 0.147 | 0.143 | 0.131 | 0.225 | 0.265 | 0.291 | 0.256 | 0.197 | 0.185 |